A partial peptide of a preproglucagon peptide comprising at least the amino acid sequence at positions 92-97 of a preproglucagon peptide is used as an effective ingredient of an antidiabetic drug.

Description of the Invention

An agent for inducing conversion of intestinal cells into insulin-producing cells in accordance with the present invention (hereinafter, referred to as "the conversion inducer") is a partial peptide of a preproglucagon peptide, in which an active ingredient is a peptide having an inductive action for converting intestinal cells into insulin-producing cells (hereinafter, referred to as a "peptide of the present invention"). The peptide of the present invention is characterized by comprising at least the amino acid sequence (His-Asp-Glu-Phe-Glu-Arg, SEQ ID NO: 2) corresponding to positions 92 to 97 of a preproglucagon peptide. As a base of the peptide sequence of the present invention, but not particularly limited to, the sequence of the preproglucagon peptide may be of a mammal such as a human being, monkey, mouse, rat, guinea pig, rabbit, dog, cat, pig, sheep, horse, or cow, a bird such a chicken, or the like. Among them, the sequence originating from a mammal is preferable. The amino acid sequence of a human preproglucagon peptide is represented by SEQ ID NO: 1 in sequence listing (GenBank/EMBL/DDBJ accession J04040).

The peptide of the present invention is not particularly limited as far as it contains the amino acid sequence represented by SEQ ID NO: 2 described above and has an activity to induce the conversion of intestinal cells into insulin-producing cells. The peptide of the present invention may be a peptide having a partial sequence of a preproglucagon peptide or a derivative thereof with a modified part of the sequence. As described above, complicated processing has been applied on preproglucagon to generate various kinds of peptides. Among them, there are GLP-1(1-37) and MPGF (a peptide consisting of amino acids at positions 84-179 of a preproglucagon peptide), each of which is a peptide that contains the amino acid sequence represented by SEQ ID NO: 2 and is reported to have a pharmacological action (Pancreas 1990 July; 5 (4): 484-8). Furthermore, it is speculated that the rest of the various kinds of peptides includes many intermediate peptides in the processing. The present invention has found the importance of the amino acid sequence represented by SEQ ID NO: 2, so that any peptide containing the above sequence is expected to have similar effects even if it is a peptide originating from preproglucagon except GLP-1(1-37).

Specific examples of the peptide of the present invention include a peptide that has any one of following amino acid sequences (a) to (i) and has an activity to induce the conversion of intestinal cells into insulin-producing cells:

(a) the amino acid sequence consisting of amino acid Nos. 92-97 in SEQ ID NO: 1;

(b) the amino acid sequence consisting of amino acid Nos. 92-117 in SEQ ID NO: 1;

(c) the amino acid sequence consisting of amino acid Nos. 92-124 in SEQ ID NO: 1;

(d) the amino acid sequence consisting of amino acid Nos. 92-128 in SEQ ID NO: 1;

(e) the amino acid sequence consisting of amino acid Nos. 84-97 in SEQ ID NO: 1;

(f) the amino acid sequence consisting of amino acid Nos. 84-117 in SEQ ID NO: 1;

(g) the amino acid sequence consisting of amino acid Nos. 84-124 in SEQ ID NO: 1;

(h) the amino acid sequence consisting of amino acid Nos. 84-179 in SEQ ID NO: 1.

Among the peptides mentioned above, preferable is the peptide having the amino acid sequence at positions 92-128 of the preproglucagon peptide. Specifically, such a peptide may be one having the amino acid sequence of the above (d). This peptide corresponds to "GLP-1(1-37)".

In the present invention, the phrase "conversion of intestinal cells into insulin-producing cells" means that, among cells that constitute the intestinal tract, cells having a potential ability to be converted to insulin-producing cells or some of them are converted to insulin-producing cells. Thus, there is no need of converting all intestinal cells into insulin-producing cells.

The peptide of the present invention may has an amino acid sequence obtained by substitution, deletion, insertion, or addition of 1-8, preferably 1-5, more preferably 1-3 amino acid residues in one of the amino acid sequences of the above (a) to (h) as far as the peptide has the activity to induce the conversion of intestinal cells into insulin-producing cells. Furthermore, the substitution, deletion, insertion, or addition of the amino acid residues is 20% or less, preferably 15% or less, more preferably 10% or less of the total length of the peptide.

In this case, examples of an amino acid sequence which is substituted, deleted, inserted or added with one or more amino acid residue include a peptide, which is known as a GLP-1(7-37) derivative, added with the amino acid sequence of SEQ ID NO: 2. For example, there is given a GLP-1(7-37) derivative sequence, which is described in U.S. Pat. No. 6,583,111 B, added with the amino acid sequence of SEQ ID NO: 2. Examples of the GLP-1(7-37) derivative include substituted amino acids shown in the following table (see Original Patent).

In addition, examples of the sequence in which one or more amino acid is deleted include a sequence in which 1 to 3 C-terminal amino acids are deleted.

Specific examples of the sequence include sequences of GLP-1(1-34), GLP-1(1-35), and GLP-1(1-36). Moreover, derivatives of those peptides include a peptide in which an N-terminal amino acid is acylated or alkylated, a peptide in which the N-terminal amino acid and/or the second amino acid relative to the N-terminal is substituted by a D-amino acid, and a peptide in which a histidine residue in the terminus is changed by an imidazole-based substituent. Examples of the acylated peptide include a peptide having a side chain of the Lys-34 residue added with an acyl group with linear or branched 6-10 carbon atoms. Examples of the imidazole-based substituent include the following substituents. Preferable is 4-imidazopropionyl (see U.S. Pat. No. 5,512,549 B).

In addition, derivatives of those peptides include a peptide in which a carbonyl group of the C-terminal amino acid residue is substituted by an alcohol group and a peptide in which the C-terminal amino acid residue is substituted by an amino group.

Moreover, the side chains of the terminal amino acid residue and/or other amino acid residues may have an amino group and/or carboxyl group with an appropriate protecting group. Formation and removal of the protecting group can be performed by applying a known method.

Typical examples of the amino protecting group include an acyl group, a formyl group, an acetyl group, an isopropyl group, a butoxycarbonyl group, a fluorenylmethoxycarbonyl group, and a carbobenzyloxy group. Each group suitably protects an amino group in the side chain of an N-terminal amino acid residue or a basic amino acid residue. Moreover, typical examples of the carboxyl protective group include a benzyl ester, a methyl ester, t-butyl ester, and p-nitrophenyl ester. Each group suitably protects an amino group in the side chain of a C-terminal amino acid residue or an acidic amino acid residue.

In addition, the peptide of the present invention includes salts thereof. When the peptide of the present invention can be in the form of the salt, the salt may be a pharmaceutically acceptable salt. Examples of the salt for an acidic group such as a carboxyl group in the formula can include: alkaline metal salts such as an ammonium salt, a sodium salt, and a potassium salt; salts of alkaline earth metals such as calcium and magnesium; an aluminum salt; a zinc salt; salts of organic amines such as triethylamine, ethanolamine, morpholine, pyrrolidine, piperidine, piperazine, and dicyclohexylamine; and salts of basic amino acids such as arginine and lysine. When a basic group is present in the formula, examples of the salt for the basic group can include: salts of inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, and hydrobromic acid; salts of organic carboxylic acid such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, succinic acid, tannic acid, butyric acid, hibenzic acid, pamoic acid, enanthic acid, decanoic acid, teoclic acid, salicylic acid, lactic acid, oxalic acid, mandelic acid, and malic acid; and salts of organic sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.

Actions of peptides excluding those specifically represented by the sequences as described above can be identified by "a method for screening the agent for inducing conversion of intestinal cells into insulin-producing cells" of the present invention, which will be described later.

The peptide of the present invention can be produced, for example, by a method of chemically synthesizing a peptide, such as a solid phase synthesis method. In addition, the peptide of the present invention can be also produced as a recombinant peptide by making use of gene recombinant techniques using DNA that encodes the peptide to express the peptide in E. coli, yeast, insect cells, animal cells, or the like. The DNA can be obtained by designing the sequence thereof depending on the frequency of codon usage of the host and carrying out the conventional method of chemically synthesizing DNA.

For instance, in the case of using E. coli, a DNA sequence encoding the peptide of the present invention is ligated to a sequence of a promoter, such as a tryptophan synthetase operon (trp) promoter, lactose operon (lac) promoter, lambda phage promoter, tac promoter, or T7 phage promoter. Preferably, a ribosome-binding sequence such as the Shine-Dalgarno sequence (SD sequence), or a transcription termination factor is further added to the DNA sequence and then the transformation of E. coli is performed using an appropriate vector. The peptide of the present invention is obtained by culturing the obtained transformant under conditions that allow the promoter to serve its function. In addition, in the case of producing the peptide of the present invention as a recombinant, a methionine residue may be added to the N-terminal of the sequence selected from the above (a) to (h).

Furthermore, the peptide of the present invention may be directly expressed as a peptide itself having a target sequence or may be expressed as a fusion protein with another protein. Besides, the peptide may be accumulated as an inclusion body in the microorganism, may be accumulated as a peptide of a soluble type in the microorganism, or may be secreted to the outside of the microorganism. Examples of the fusion protein include fusion proteins with maltose binding protein, glutathione S-tranferase, and histidine tag (His-Tag).

In addition, the peptide of the present invention may be one modified to prolong the blood clearance thereof. For example, the peptide may be one in which a polyoxyalkyl polyol group is bound to a reactive group in the peptide. Preferably, the polyoxyalkyl polyol group is a polyethylene glycol group.

The peptide of the present invention can be purified from the culture by the conventional peptide purification method such as salting out, ion-exchange chromatography, or centrifugal separation. In addition, the conventional methods well known to one skilled in the art can be applied to the chemical synthesis of DNA, ligation between a DNA fragment and a vector, transformation, and so on. Those methods are described, for example, in Sambrook, J., Fritsch, E. F., and Maniatis, T., "Molecular Cloning A Laboratory Manual, Third Edition", Cold Spring Harbor Laboratory Press, (2001).

The conversion of intestinal cells into insulin-producing cells can be induced by allowing an agent for inducing conversion of intestinal cells into insulin-producing cells, the inducing agent containing the peptide of the present invention, to act on the intestinal cells. More specifically, the intestinal cells are cultured in the presence of the peptide of the present invention and if required a growth factor. The intestinal cells include cells originating from the duodenum, the small intestine (including the jejunum and ileum) and the large bowl (including the caecum, colon and rectum). Those cells are not particularly limited as far as they are collected from the intestine of a mammal. Preferably, cells are isolated from the small intestine. As a method of isolating such cells, it is not particularly limited, but for example, the method shown in the examples section can be applied. The concentration of the peptide of the present invention at the time of inducing the conversion of intestinal cells into insulin-producing cells is preferably in the range of 1 nm/l to 1,000 nm/l.

Each of the insulin-producing cells obtained as described above can be used as a therapeutic implant for a human being or animal suffering from diabetes. Therefore, the present invention provides a therapeutic method for diabetes, which includes transplanting the implant obtained in this way into the body of the human being or animal.

The conversion of intestinal cells into insulin-producing cells can be induced by administering the peptide of the present invention to a mammal such as a human being, monkey, mouse, rat, guinea pig, rabbit, dog, cat, pig, sheep, horse, or cow. The induction of the insulin-producing cells is effective for diabetes prevention and treatment. Therefore, the present invention provides a preventive or therapeutic method for diabetes using the peptide of the present invention and a preventive or antidiabetic drug containing the peptide or the conversion inducer of the present invention (hereinafter, collectively referred to as a "antidiabetic drug").

Hereinafter, the conversion inducer and the antidiabetic drug of the present invention will be described.

Dosage forms to be applied for the conversion inducer and antidiabetic drug of the present invention include an injection, sublingual agent, inhalation, transdermal poultice, tablet, capsule, fine granule, syrup, suppository, ointment, and eye drops. Among them, the injection, sublingual agent, and trandermal poulitice are preferable. In addition, depending on the dosage form, the agent may be blended with a pharmaceutically acceptable excipient such as lactose, potato starch, calcium carbonate, or sodium alginate. Furthermore, the agent may be also blended with other materials conventionally used for pharmaceuticals, for example, ingredients including proteins such as serum albumin, salts for buffer action or osmoregulation, carriers, and excipients. For the injection, a solvent to be used may be distilled water for injection, a physiological saline, Ringer's solution, or the like and a dispersant may be added to the solvent.

The peptide of the present invention to be incorporated in a conversion inducer or antidiabetic drug may be used alone or as a mixture of two or more peptides.

A dosage of the antidiabetic drug of the present invention is not particularly limited as far as the dosage serves the requirement for treating the disease. More specifically, the dosage varies depending on conditions including species, age, sexuality, body weight of the subject that requires such a treatment, an oral or parenteral (such as intravenous, subcutaneous, intramuscular, suppository, enema, ointment, poultice, sublingual, and ophthalmic) route or the like. Generally, for intravenous administration to human subjects, the dosage of the peptide of the present invention is in the range of 0.1 .mu.g/kg to 10 mg/kg, preferably in the range of 1 .mu.g/kg to 1 mg/kg per day per adult.

The antidiabetic drug of the present invention is effective for the treatment and prevention of diabetes and its related diseases involving a decrease in function of glucose tolerance. Those diseases include: diabetes, such as type I diabetes (insulin-dependent diabetes) and type II diabetes (non-insulin-dependent diabetes), malnutrition-related diabetes, and diabetes of another type involved in a specific disease state or symptoms; functional disorders of glucose tolerance; and gestational diabetes. However, the agent is not limited to those diseases. The agent of the present invention can be applied for a wide variety of diabetes. It is conceivable that the antidiabetic drug of the present invention will act on intestinal cells to induce the transformation thereof into insulin-producing cells to secrete insulin therefrom. Thus, the agent is expected to be effective for patients having deteriorated pancreas functions.

Moreover, the conversion inducer or antidiabetic drug of the present invention can be used in combination with a general antidiabetic drug. For example, the general antidiabetic drug includes one or a combination or mixture of two or more of the following drugs: an insulin formulation, an insulin derivative, an insulin-like agent, an insulin-secreting promoter, an insulin-resistance improving agent, a biguanide agent, a gluconeogenesis inhibitor, a sugar absorption inhibitor, a renal glucose reabsorption inhibitor, a .beta.3-adrenaline receptor agonist, a glucagon-like peptide-1 (7-37), a glucagon-like peptide-1 (7-37) analog, a glucagon-like peptide-1 receptor agonist, a dipeptidyl peptase IV inhibitor, an aldose reductase inhibitor, an advanced glycation end-product production inhibitor, a glycogen synthetase kinase-3 inhibitor, a glycogen phosphorylase inhibitor, an anti-hyperlipemia drug, an appetite suppressant, a lipase inhibitor, an antihypertensive agent, a peripheral circulation improving drug, an antioxidant, and a therapeutic agent for diabetic neuropathy.

Examples of specific compounds of drugs to be used in combination and preferable diseases to be treated are shown below, but the present invention is not limited thereto. The specific compounds include a free form and/or other pharmaceutically acceptable salts thereof.

Examples of the insulin formulation include NPH, lente, ultralente and insulin capable of being absorbed through the lung.

The insulin derivative refers to one that has an insulin effect in a protein or peptide derived from insulin. Examples of the insulin derivative include lispro, B10Asp, and glargine.

The insulin-like agent refers to one excluding the insulin derivative, which exerts a blood sugar decrease effect by exerting an insulin physiological effect such as a sugar intake promoting effect to a cell to some extent without relying on insulin. Examples of the insulin-like agent include an insulin receptor kinase stimulator (such as L-783281, TER-17411, CLX-0901, or KRX-613) and vanadium.

The insulin-secreting promoter refers to one that exerts a blood sugar decrease effect by acting a pancreatic .beta. cell to increase the amount of insulin secreted in blood. Examples of the insulin-secreting promoter include a sulfonylurea agent (such as tolbutamide, chlorpropamide, trazamide, acetohexamide, gliclazide, glimepiride, glipizide, or glibenclamide (glyburide)), a meglitinide (such as nateglinide, repaglinide, or mitiglinide), and an ATP-sensitive potassium channel inhibitor excluding the sulfonylurea agent and meglitinide (such as BTS-67-582).

The insulin-resistance improving agent refers to one that exerts a blood sugar decrease effect by enhancing the insulin effect in a target tissue of insulin. Examples of the insulin-resistance improving agent include a peroxisome proliferator activating receptor (PPAR) .gamma. agonist (such as a thiazolidinedione compound including pioglitazone, rosiglitazone, troglitazone, and ciglitazone; or a non-thiazolidinedione compound including GI-262570, GW-1929, JTT-501, and YM-440), a PPAR .gamma. antagonist (such as a bisphenol A diglycidyl ether or LG-100641), a PPAR .alpha. agonist (such as a fibrate compound including clofibrate, bezafibrate, and clinofibrate; or a non-fibrate compound), a PPAR .alpha./.gamma. agonist (such as KRP-297), a retinoid X receptor agonist (such as LG-100268), a retinoid X receptor antagonist (such as HX 531), and a protein tyrosine phosphatase-1B inhibitor (such as PTP-112).

The biguanide agent refers to one that exerts a blood sugar decrease effect by a gluconeogenesis inhibitory effect in the liver, an anaerobic glycolysis promoting effect in the tissue, or insulin resistance improving effect in the periphery. Examples of the biguanide agent include metformin, phenformin, and buformin.

The gluconeogenesis inhibitor refers to one that exerts a blood sugar decrease effect by inhibiting gluconeogenesis mainly. Examples of the gluconeogenesis inhibitor include a glucagon secreting inhibitor (such as M&B 39890A), a glucagon receptor antagonist (such as CP-99711, NNC-92-1687, L-168049, or BAY 27-9955), and a glucose-6-phosphatase inhibitor.

The sugar absorption inhibitor refers to one that exerts a blood sugar decrease effect by inhibiting enzymatic digestion of carbohydrates in foods in the gastrointestinal tract to inhibit or delay absorption of sugar to the body. Examples of the sugar absorption inhibitor include an .alpha.-glucosidase inhibitor (such as acarbose, voglibose, or miglitol), and an .alpha.-amylase inhibitor (such as AZM-127).

The renal glucose reabsorption inhibitor refers to one that exerts a blood sugar decrease effect by inhibiting reabsorption of sugar to the renal tubule. Examples of the renal glucose reabsorption inhibitor include a sodium-dependent glucose transporter inhibitor (such as T-1095 or phloridzin).

The .beta.3-adrenaline receptor agonist refers to one that exerts an obesity or hyperinsulinemia improving effect by stimulating a .beta.3-adrenaline receptor in fat to promote oxidation of a fatty acid and to consume energy. Examples of the .beta.3-adrenaline receptor agonist include CL-316243 and TAK-677.

Examples of the glucagon-like peptide-1 (7-37) analog include exendin-4 and NN-2211. Examples of the glucagon-like peptide-1 (7-37) receptor agonist include AZM-134. Examples of the dipeptidyl peptidase IV inhibitor include NVP-DPP-728. Each of the glucagon-like peptide-1 (7-37) analog, the glucagon-like peptide-1 (7-37) receptor agonist, the dipeptidyl peptidase IV inhibitor, and the glucagon-like peptide-1 (7-37) refers to one that exerts a diabetes improving effect by imitating or enhancing a glucagon-like peptide-1 (7-37) effect in a cell.

The aldose reductase inhibitor, among those preferred to treat a diabetic complication, refers to one that decreases intracellular sorbitol, by inhibiting an aldose reductase, which is excessively accumulated by polyol metabolic pathway enhancement caused by sustaining a high blood-sugar state that is observed in a tissue in which a diabetic complication is developed. Examples of the aldose reductase inhibitor include epalrestat, tolrestat, fidarestat, and zenerestat.

The advanced glycation end-product production inhibitor, among those preferred to treat a diabetic complication, refers to one that reduces a cell disorder by inhibiting advanced glycation end product production increased by sustaining a high blood-sugar state in diabetes condition. Examples of the advanced glycation end-product production inhibitor include NNC-39-0028 and OPB-9195.

Examples of the glycogen synthetase kinase-3 inhibitor include SB-216763 and CHIR-98014. Examples of the glycogen phosphorylase inhibitor include CP-9149.

Examples of the anti-hyperlipemia drug include a hydroxymethylglutaryl coenzyme A (HMGCoA) reductase inhibitor (such as pravastatin, simvastatin, fluvastatin, or atorvastatin), a fibrate drug (such as clofibrate, bezafibrate, or simfibrate), and a bile acid excretion promoter.

Examples of the appetite suppressant include sibutramine and mazindol. Examples of the lipase inhibitor include orlistat.

Examples of the antihypertension agent include an angiotensin converting enzyme inhibitor (such as captopril or alacepril), an angiotensin II receptor antagonist (such as candesartan cilexetil or valsartan), a calcium antagonist (such as cilnidipine, amlodipine, or nicardipine), a diuretic (such as trichlormethazide or spironolactone), and a sympathetic nerve blocking agent (such as clonidine or reserpine).

Examples of the peripheral circulation improving drug include ethyl icosapentate. Examples of the antioxidant include lipoic acid and probucol.

Examples of the therapeutic agent for diabetic neuropathy include mecobalamin and mexiletine hydrochloride.

The peptide of the present invention can be used for the screening of an agent for inducing conversion of intestinal cells into insulin-producing cells. The present invention allows the intestinal cells to be converted to the insulin-producing cells, so that the screening of the conversion inducer can be performed using intestinal cells. At this time, the peptide of the present invention is used as a positive control. Specifically, the screening is performed by the following steps of:

(a) culturing the intestinal cells in the presence of a test material;

(b) determining expression of an insulin-producing cell marker for the cells after the culture; and

(c) making a comparison between the expression of the marker in the presence of the test material and the expression of the marker in the presence of the conversion inducer.

The intestinal cells used in the screening process are not particularly limited as far as the cells are collected from the intestinal tract of a mammal. Preferably, however, the cells are small intestinal cells isolated by the method described in the example described later. The reaction between the cells and a test material or a conversion inducer is generally performed by culture at 35 to 40.degree. C. for several hours to several tens of days, preferably at 36.5 to 37.5.degree. C. for 1 to 20 days. After the reaction with the test material or the conversion inducer, the presence of conversion of the cells into insulin-producing cells and the conditions of the transformation are investigated.

The expression of an insulin-producing cell marker is measured for confirming whether the intestinal cells are converted to insulin-producing cells or not. Here, the "insulin-producing cell marker" is a protein being expressed and produced (secreted) specifically in the insulin-producing cells or a gene encoding the protein. For instance, the marker can be identified by examining the production and insulin secretion. In addition, the transcription factor group (neurogenin 3 (ngn3), neuro D/BETA 2, pax-4, Nkx 6.1, and hepatocyte nuclear factor 6 (HNF-6)) that controls the differentiation of secretory cells in the pancreas can be also used as the above marker.

The peptide of the present invention can be also used for the screening of an inhibitor of the conversion of intestinal cells into insulin-producing cells. For instance, the screening is performed by the following steps of:

(a') culturing the intestinal cells in the presence of the peptide of the present invention and a test material; and

(b') determining expression of an insulin-producing cell marker for the cells after the culture.

Furthermore, the peptide of the present invention can be applied in the method of searching a receptor to the partial peptide of a preproglucagon peptide having the activity to induce the conversion of intestinal cells into insulin-producing cells. For instance, the method is performed by the following steps of:

(a'') transfecting a gene originating from an animal into an animal cell; and

(b'') effecting the peptide of the present invention on the transgenic cell obtained in the step (a'') to observe binding between a peptide in the inducing agent and the transgenic cell or a change in the transgenic cell.
 

Claim 1 of 1 Claim

1. A method of treating type 1 diabetes, consisting of: administering to a subject in need thereof an antidiabetic drug consisting of amino acid Nos. 92-128 in SEQ ID NO: 1 and optionally one or more pharmaceutically acceptable excipients, wherein conversion of intestinal cells into insulin-producing cells is induced.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.